ORKA logo

Oruka Therapeutics Inc. (ORKA)

$96.32

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ORKA

Market cap

$6.53B

EPS

-2.1

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

-0.318624

Price on ORKA

Previous close

$99.24

Today's open

$98.51

Day's range

$95.05 - $100.77

52 week range

$25.23 - $115.52

Profile about ORKA

CEO

Lawrence Klein

Employees

68

Headquarters

Menlo Park, CA

Exchange

NASDAQ Global Market

Shares outstanding

67822359

Issue type

Common Stock

ORKA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ORKA

Oruka Therapeutics, Inc. (ORKA) Presents at UBS Global Biopharma Conference 2026 Transcript

Oruka Therapeutics, Inc. (ORKA) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • a day ago

news preview

Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A

news source

GlobeNewsWire • Nov 9, 2026

news preview

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference Date: November 10, 2026 Presentation Time: 11:00 AM EST Stifel 2026 Healthcare Conference Date: November 11, 2026 Presentation Time: 4:00 PM EST UBS Global Biopharma Conference Date: November 17, 2026 Presentation Time: 4:00 PM GMT Jefferies Global Healthcare Conference Date: November 18, 2026 Presentation Time: 4:30 PM GMT Webcasts and replays of Oruka's presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its 600-milligram regimen achieved complete skin clearance, measured by PASI 100, in 61% of participants at week 16, while 86% achieved PASI 90.

news source

MarketBeat • Oct 27, 2026

news preview

Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Monday reported positive Week 16 results from its EVERLAST-B Phase 2b clinical trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.

news source

Benzinga • Oct 26, 2026

news preview

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript

news source

Seeking Alpha • Oct 26, 2026

news preview

Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into Phase 3 trials in 1H 2027 52-week EVERLAST-A results on track for December 2026 ORKA-002 16-week results from ORCA-SURGE Phase 2 in psoriasis on track for 1Q 2027 Management to host conference call today at 8:00 a.m. ET MENLO PARK, Calif.

news source

GlobeNewsWire • Oct 26, 2026

news preview

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

news source

GlobeNewsWire • Oct 25, 2026

news preview

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

Oruka Therapeutics is positioned as a leader in ultra-long-acting injectable treatments for psoriasis, with ORKA-001 showing class-leading efficacy. ORKA-001's PASI 100 and PASI 90 rates at Week 28 reinforce its durability, while a replicated response in the crossover cohort strengthens confidence in trial results. ORKA's $1.1B cash balance, exclusive Hypercon technology license, and pipeline breadth provide funding through BLA and strategic flexibility amid rising R&D spend.

news source

Seeking Alpha • Oct 18, 2026

news preview

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.

news source

Zacks Investment Research • Sep 24, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Oruka Therapeutics Inc.

Open an M1 investment account to buy and sell Oruka Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ORKA on M1